BVF Inc. IL Takes $48.23 Million Position in Invivyd, Inc. $IVVD

BVF Inc. IL acquired a new stake in Invivyd, Inc. (NASDAQ:IVVD) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 19,525,000 shares of the company’s stock, valued at approximately $48,227,000. Invivyd makes up approximately 1.6% of BVF Inc. IL’s portfolio, making the stock its 22nd largest holding. BVF Inc. IL owned 8.38% of Invivyd at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of IVVD. Invesco Ltd. grew its holdings in Invivyd by 190.6% during the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after purchasing an additional 71,485 shares during the period. AQR Capital Management LLC grew its holdings in Invivyd by 2,051.0% during the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after purchasing an additional 391,617 shares during the period. Marshall Wace LLP bought a new position in Invivyd during the second quarter worth about $158,000. Jane Street Group LLC bought a new position in Invivyd during the second quarter worth about $147,000. Finally, Vanguard Group Inc. grew its holdings in Invivyd by 46.7% during the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock worth $6,339,000 after purchasing an additional 1,834,970 shares during the period. Institutional investors own 70.36% of the company’s stock.

Invivyd Stock Performance

Shares of Invivyd stock opened at $0.93 on Thursday. The firm has a 50-day moving average of $1.29 and a 200-day moving average of $1.74. The stock has a market cap of $274.34 million, a PE ratio of -3.00 and a beta of 0.63. Invivyd, Inc. has a 52-week low of $0.48 and a 52-week high of $3.07.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.05). The company had revenue of $13.74 million during the quarter, compared to the consensus estimate of $18.04 million. Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%. Equities research analysts predict that Invivyd, Inc. will post -0.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on IVVD. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a report on Wednesday, April 29th. Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Invivyd in a report on Monday. Finally, BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of Invivyd in a report on Tuesday, June 9th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.